Study of a new therapy before surgery for high-risk kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new treatment given before surgery for high-risk kidney cancer that hasn't spread far. The goal is to see if it can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of kidney cancer called clear cell renal cell carcinoma, and it is either high-risk localized or locally advanced (meaning it hasn't spread to distant organs).
- You have not previously been treated with an immune checkpoint inhibitor (a type of drug that helps your immune system fight cancer).
- You are physically able to carry out daily activities (ECOG performance status 0 or 1).
- You are planned to receive treatment before surgery (neoadjuvant therapy) and then have the tumor surgically removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This study tests a new combination of medicines for people with advanced clear cell kidney cancer that has gotten worse after first treatment. The combination includes two immunotherapy drugs (iparomlimab and tuvonralimab) plus one of two targeted therapy pills (lenvatinib or axitinib). The goal is to see if this approach can help control the cancer.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
Hear when a new Urologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.